Terns Pharmaceuticals Inc...

NASDAQ: TERN · Real-Time Price · USD
7.07
0.30 (4.43%)
At close: Aug 15, 2025, 3:59 PM

Terns Pharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
n/a n/a n/a n/a n/a n/a 1.32M n/a n/a n/a n/a n/a n/a n/a 1M n/a n/a n/a
Cost of Revenue
108K n/a n/a n/a 240K 236K 220K 222K 217K 222K 485K 252K 269K 278K 114K 107K 119K 172K
Gross Profit
-108K n/a n/a n/a -240K -236K 1.1M -222K -217K -222K -485K -252K -269K -278K 886K -107K -119K -172K
Operating Income
-27.38M -27.43M -25.95M -24.94M -25.54M -25.45M -24.06M -33.18M -21.16M -24.16M -16.83M -17.29M -14.08M -13.82M -13.88M -11.87M -10.82M -13.3M
Interest Income
3.35M 3.64M 4.14M 3.09M 2.88M 3.18M 3.33M 3.48M 3.4M 2.69M 1.33M 499K 214K 69K 55K 49K 55K 11K
Pretax Income
-24.03M -23.82M -21.76M -21.88M -22.68M -22.28M -20.97M -29.71M -17.82M -21.47M -15.5M -16.81M -13.92M -13.75M -13.81M -11.81M -10.72M -13.3M
Net Income
-24.09M -23.91M -21.8M -21.95M -22.74M -22.37M -21.02M -29.77M -17.9M -21.53M -15.82M -16.82M -13.93M -13.77M -14.25M -11.84M -10.74M -13.34M
Selling & General & Admin
6.92M 8.71M 7.95M 9.77M 7.18M 6.62M 6.38M 18.35M 7.01M 7.1M 6.17M 5.13M 5.42M 5.69M 5.42M 4.71M 4.86M 4.56M
Research & Development
20.35M 18.72M 18M 15.17M 18.35M 18.59M 17.46M 14.83M 14.15M 17.06M 10.66M 12.16M 8.66M 8.14M 9.46M 7.15M 5.96M 8.73M
Other Expenses
n/a n/a n/a n/a n/a -12K n/a -5K -60K -4K -4K -14K -54K 4K 10K 4K 39K -13K
Operating Expenses
27.27M 27.43M 25.95M 24.94M 25.54M 25.21M 23.84M 33.18M 21.16M 24.16M 16.83M 17.29M 14.08M 13.82M 14.88M 11.87M 10.82M 13.3M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Selling & Marketing Expenses
n/a n/a n/a n/a n/a -236K -220K n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
27.38M 27.43M 25.95M 24.94M 25.54M 25.45M 24.06M 33.18M 21.16M 24.16M 16.83M 17.29M 14.08M 13.82M 14.88M 11.87M 10.82M 13.3M
Income Tax Expense
64K -88K 40K 62K 61K 97K 49K 58K 72K 60K 318K 13K 6K 21K 435K 20K 14K 39K
Shares Outstanding (Basic)
91.58M 91.47M 91.24M 77.82M 74.46M 74.4M 72.33M 71.53M 71.36M 69.78M 54.7M 38.51M 25.3M 25.27M 25.27M 25.15M 25.11M 15.16M
Shares Outstanding (Diluted)
91.58M 91.47M 91.24M 77.82M 74.46M 74.4M 72.33M 71.53M 71.36M 69.78M 54.7M 38.51M 25.3M 25.27M 25.27M 25.15M 25.11M 15.16M
EPS (Basic)
-0.26 -0.26 -0.24 -0.28 -0.31 -0.3 -0.29 -0.42 -0.25 -0.31 -0.29 -0.44 -0.55 -0.55 -0.56 -0.47 -0.43 -0.88
EPS (Diluted)
-0.26 -0.26 -0.24 -0.28 -0.31 -0.3 -0.29 -0.42 -0.25 -0.31 -0.29 -0.44 -0.55 -0.55 -0.56 -0.47 -0.43 -0.88
EBITDA
-23.92M -27.43M -25.73M -24.73M -25.3M -25.36M -23.99M -33.11M -21.16M -24.16M -16.59M -17.04M -13.81M -13.47M -13.76M -11.76M -10.7M -13.12M
EBIT
-24.03M -27.43M -25.95M -24.94M -25.54M -25.45M -24.06M -33.18M -21.16M -24.16M -16.83M -17.29M -14.08M -13.82M -13.88M -11.87M -10.82M -13.3M
Depreciation & Amortization
108K 169K 214K 206K 240K 236K 220K 222K 217K 222K 485K 252K 269K 278K 114K 107K 119K 172K